756751-75-4

Basic information

• Product Name: 1-(3-BENZYLOXY-PHENYL)-PIPERAZINE
• Synonyms: 1-(3-BENZYLOXY-PHENYL)-PIPERAZINE
• CAS NO: 756751-75-4
• Molecular Formula: C17H20N2O
• Molecular Weight: 268.35
• Product Categories: pharmacetical
• Mol File: 756751-75-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 450.2°C at 760 mmHg
• Flash Point: 226.1°C
• Appearance: /
• Density: 1.106g/cm³
• Vapor Pressure: 2.69E-08mmHg at 25°C
• Refractive Index: 1.582
• PKA: 8.93±0.10(Predicted)
• CAS DataBase Reference: 1-(3-BENZYLOXY-PHENYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-BENZYLOXY-PHENYL)-PIPERAZINE(756751-75-4)
• EPA Substance Registry System: 1-(3-BENZYLOXY-PHENYL)-PIPERAZINE(756751-75-4)

Safety Data

• Hazardous Substances Data: 756751-75-4(Hazardous Substances Data)

Usage

General Description

1-(3-BENZYLOXY-PHENYL)-PIPERAZINE is a chemical compound with the molecular formula C19H24N2O. It is a piperazine derivative and belongs to the class of aromatic piperazine derivatives. 1-(3-BENZYLOXY-PHENYL)-PIPERAZINE is commonly used in medicinal chemistry and pharmaceutical research as a building block for the synthesis of various bioactive molecules and drugs. Its structure contains a piperazine ring with a benzyl ether group attached to a phenyl ring, making it a valuable intermediate for the development of potential therapeutic agents. Additionally, 1-(3-BENZYLOXY-PHENYL)-PIPERAZINE has been studied for its potential as a serotonin receptor ligand and has shown promise in the treatment of various neurological and psychiatric disorders.

InChI:InChI=1/C17H20N2O/c1-2-5-15(6-3-1)14-20-17-8-4-7-16(13-17)19-11-9-18-10-12-19/h1-8,13,18H,9-12,14H2

Upstream product

• 53087-13-1 3-(benzyloxy)phenyl bromide 

Relevant articles and documents

Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents

We developed a focused set of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant and antinociceptive properties. These hybrid compounds demonstrated broad-spectrum protective activity in a range of mouse models, such as the maximal electroshock (MES) test, the pentylenetetrazole-induced seizures (scPTZ), and the 6 Hz (32 mA) seizures. Compound 22 showed the most potent anticonvulsant activity (ED50 MES = 23.7 mg/kg, ED50 6 Hz (32 mA) = 22.4 mg/kg, ED50 scPTZ = 59.4 mg/kg). In addition, 22 revealed potent efficacy in the formalin-induced tonic pain. These in vivo activities of 22 are likely mediated by several targets and may result from the inhibition of central sodium/calcium currents and transient receptor potential vanilloid 1 (TRPV1) receptor antagonism. Finally, the lead compound 22 revealed drug-like absorption, distribution, metabolism, excretion, toxicity (ADME-Tox) properties in the in vitro assays, making it a potential candidate for further development in epilepsy and neuropathic pain indications.